

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human CXCL17/VCC-1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25% cross-reactivity with recombinant mouse CXCL17 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2B</sub> Clone # 422208
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human CXCL17/VCC-1 Leu24-Leu119 Accession # Q6UXB2
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 µg/mL	Recombinant Human CXCL17 (Catalog # 4207-DM)
<b>Immunocytochemistry</b>	8-25 µg/mL	Immersion fixed A549 human lung carcinoma cell line
<b>Intracellular Staining by Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

CXCL17, also known as dendritic cell and monocyte chemokine-like protein (DMC) and VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation site. Cleavage of a 23 amino acid (aa) signal sequence yields the mature 96 aa human CXCL17. CXCL17 is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS-activated peripheral blood monocytes and dendritic cells (1). CXCL17 expression is increased in endothelial cells when they are induced to form tubes *in vitro* (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). CXCL17, plus two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show a correlated expression pattern with VEGF in primary lung, breast and esophageal tumors (2). CXCL17 is, therefore, suggested to play a role in tumor angiogenesis. Mature human CXCL17 shares 73%, 71% and 64% amino acid sequence identity with bovine, mouse and rat CXCL17, respectively.

## References:

1. Pisabarro, M.T. *et al.* (2006) *J. Immunol.* **176**:2069.
2. Weinstein, E.J. *et al.* (2006) *Biochem. Biophys. Res. Commun.* **350**:74.